Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...

Microwave ablation plus chemotherapy significantly improves progression-free survival in advanced NSCLC without increasing toxicity compared to chemotherapy alone. The combination treatment leverages ...

Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...

Inhibrx Biosciences, Inc. stays a Strong Buy with Q2 2026 ozekibart BLA catalyst, 2026 PFS data, and Ewing sarcoma updates.

Please provide your email address to receive an email when new articles are posted on . The addition of pyrotinib to trastuzumab and docetaxel improved 4-year OS vs. placebo for patients with ...

Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...

Zanidatamab plus chemotherapy delays progression or death in patients with untreated locally advanced or metastatic gastroesophageal adenocarcinoma.

First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but statistically significant increase in progression-free survival (PFS) compared ...

The HER2CLIMB-05 study assessed the efficacy and safety of adding tucatinib to maintenance therapy with trastuzumab/pertuzumab in patients with HER2+ metastatic breast cancer.

Please provide your email address to receive an email when new articles are posted on . Fixed-duration acalabrutinib plus venetoclax improved outcomes for untreated chronic lymphocytic leukemia ...

Cyramza plus Tagrisso significantly extended PFS in TKI-naïve EGFR-mutant NSCLC patients compared to Tagrisso alone, with a median PFS of 24.8 vs. 15.6 months. PFS benefits were consistent across ...